Peptides
BPC-157 went from a peptide nobody outside a Croatian lab had heard of to the most searched compound in the injury-recovery world in about five years. In 2026 it also became the subject of an FDA advisory committee vote, which changed its regulatory story without changing its evidence.
Here is what has actually been shown, in rats and in people, what the committee decided, and how to think about it if you are considering it.
BPC-157 is a chain of fifteen amino acids taken from a larger protein found in human gastric juice. The name stands for Body Protection Compound. It was isolated and has been studied almost entirely by a group at the University of Zagreb led by Predrag Sikiric, which has published well over a hundred papers on it since the 1990s. It is stable in stomach acid, which is unusual for a peptide and why it can be given orally as well as by injection.
In rats, BPC-157 has been reported to accelerate healing of tendons, ligaments, muscle, bone, skin, the gut lining and blood vessels. The proposed mechanisms include stimulating new blood vessel growth, activating growth factor pathways in tendon cells, and modulating the nitric oxide system.
The volume of this work is large. Its weaknesses are also large: nearly all of it comes from one laboratory, the doses vary widely, the injury models are artificial, and independent replication is thin. Rat tendon healing at 10 micrograms per kilogram tells you something is happening. It does not tell you what happens in a 40-year-old man's rotator cuff.
When the FDA reviewed the compound for its July 2026 advisory meeting, its scientists summarised the available human studies, five trials, as short in duration, small in size, and insufficient to establish safety or effectiveness for the conditions being considered. That is the honest state of the human evidence. The effect people report may be real. It has not been measured in a way that proves it.
September 2023. The FDA placed BPC-157 in Category 2 of its bulk drug substances list, meaning compounding pharmacies could not legally prepare it. Most of the clinics selling it in the United States stopped, and the grey market grew.
April 2026. The FDA removed BPC-157 and eleven other peptides, including TB-500, MOTS-c, GHK-Cu and Semax, from Category 2. This was not an approval. The original nominations were withdrawn and the substances went back to being unevaluated.
July 23, 2026. The Pharmacy Compounding Advisory Committee narrowly voted to recommend adding BPC-157 to the list of substances pharmacies may compound, along with KPV, TB-500, MOTS-c, Semax and Epitalon. The vote is advisory. The FDA still has to accept it and go through formal rulemaking with public comment before anything changes.
As of this writing, October 2026, BPC-157 is not approved as a drug anywhere, not legal to sell as a dietary supplement in the United States, not yet legally compoundable, and prohibited at all times by WADA under category S0. Anyone telling you the FDA "approved" it in 2026 has misread the news.
BPC-157 has no approval from the CDSCO and is not available through any pharmacy. What is sold is research-grade material from online sellers, with no regulatory oversight of purity, dose or sterility. Independent testing of grey-market peptides internationally has found underdosed vials, wrong compounds, and bacterial contamination. If you use it, the supplier's third-party certificate of analysis is the only protection you have, and it is worth demanding for every batch.
The peptide database lists BPC-157 with its evidence grade, reported dose ranges and the interactions worth knowing, alongside the other compounds it is commonly stacked with.
None of this is a protocol. It is a description of what people do, so that anyone who does it does it less badly.
Typical reported use is 250 to 500 micrograms once or twice daily, by subcutaneous injection, for four to eight weeks. Injecting near the injured area is common, though the rat data does not show a clear advantage for local over systemic dosing. Oral capsules exist and are used mostly for gut complaints. It is often paired with TB-500, a synthetic fragment of thymosin beta-4, on the theory that the two work through different pathways. The BPC-157 and TB-500 protocol builder lays out the reported dose ranges, timing and duration for each and for the pair, with the caveats attached to every number.
Reconstitution is where most errors happen. A 5 mg vial dissolved in 2 ml of bacteriostatic water is 2,500 mcg per ml, which makes 250 mcg a 0.1 ml draw on an insulin syringe. Get that wrong by a decimal and you have taken ten times the dose. The reconstitution engine does the arithmetic and shows the syringe markings.
It might be a reasonable experiment for an adult with a nagging soft-tissue injury who has already done the boring things: rehab, load management, sleep, protein, and time. It is not for anyone who is drug tested, anyone with a cancer history, anyone pregnant, or anyone who expects it to replace rehab.
BPC-157 has a large body of rat evidence, mostly from one lab, and human evidence that the FDA's own scientists called insufficient. In 2026 it was removed from a restricted list and an advisory committee narrowly recommended allowing it to be compounded, but it remains unapproved, illegal as a supplement, and banned by WADA. If you use it, buy tested material, get the reconstitution maths right, and treat it as an experiment alongside rehab, not instead of it.
No. In July 2026 an FDA advisory committee voted narrowly to recommend allowing pharmacies to compound it, but the FDA has not acted on that recommendation and it is not an approval. It is not a legal dietary supplement.
Nobody knows with confidence. The rat evidence is extensive. The human evidence consists of a few small, short studies that the FDA's reviewers considered insufficient to establish safety or effectiveness.
Reported use is 250 to 500 micrograms once or twice daily by subcutaneous injection for four to eight weeks. These figures come from user reports, not from controlled trials.
Yes. It is prohibited at all times under category S0, non-approved substances, on the 2026 Prohibited List. FDA reclassification does not change that.
It has no CDSCO approval and is not sold through pharmacies. Material bought online is unregulated research-grade product with no guarantee of purity or dose.
No human data exists. The concern is theoretical: it promotes blood vessel growth, which tumours also depend on. Anyone with a cancer history should avoid it.
This article is educational and is not medical advice, and is not a recommendation to use any compound. BPC-157 is not an approved medicine. See the medical disclaimer.
Want a programme built around your own numbers?
Work With Dinesh
Newsletter
One email when a new guide, calculator or breakdown goes live. Nothing else.
